Research progress of the dupilumab-induced psoriasiform reaction
SUN Jie
SUN Feng-qing
GONG Yue
Abstract：Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain,which has been widely used in moderate-to-severe atopic dermatitis in uncontrolled patients in recent years and has proven to be effective.However,there is an adverse reaction which is noteworthy and unrecorded in phase Ⅲ study.It has been found that dupilumab can induce psoriasiform eruption in some patients.The histologic characterization of most patients shows a typical psoriasiform reaction pattern,and sometimes minimal spongiosis can be observed.The pathogenesis of this reaction could be related to type 1 helper T cells/type 2 helper T cells immune drift,the function of antibacterial peptides and neutrophils,or genetic predisposition.Therefore,this review elaborates on the clinical manifestation,histopathologic features and possible pathogenesis of dupilumab-induced psoriasiform reaction,aiming to provide evidence for the identification and treatment of dupilumab-induced psoriasiform reaction..
Keywords：DermatitisatopicPsoriasisBiological agentaupilumabAdverse reaction
Publication Date：2023-12-10
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 361-364,373 )